Anti-tumor agents 255: Novel glycyrrhetinic acid–dehydrozingerone conjugates as cytotoxic agents by Tatsuzaki, Jin et al.
Antitumor Agents 255. Novel Glycyrrhetinic Acid-
Dehydrozingerone Conjugates as Cytotoxic Agents
Jin Tatsuzakia, Masahiko Taniguchia, Kenneth F. Bastowb, Kyoko Nakagawa-Gotoa, Susan
L. Morris-Natschkea, Hideji Itokawaa, Kimiye Babac, and Kuo-Hsiung Leea,*
aNatural Products Research Laboratories, School of Pharmacy, University of North Carolina, Chapel Hill,
NC 27599-7360, USA
bDivision of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina,
Chapel Hill, NC 27599-7360, USA
cDepartment of Pharmacognosy, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki,
Osaka 569-1094, Japan
Abstract
Esterification of glycyrrhetinic acid (GA) with dehydrozingerone (DZ) resulted in a novel cytotoxic
GA-DZ conjugate. Based on this exciting finding, we conjugated eleven different DZ analogs with
GA or other triterpenoids, including oleanoic acid (OA) or ursolic acid (UA). In an in vitro anticancer
assay using nine different human tumor cell lines, most of the GA-DZ conjugates showed significant
potency. Particularly, compounds 5, 29, and 30 showed significant cytotoxic effects against LN-Cap,
1A9, and KB cells with ED50 values of 0.6, 0.8, and 0.9 μM, respectively. Similar conjugates between
DZ and OA or UA were inactive suggesting that the GA component is critical for activity. Notably,
although GA-DZ conjugates showed potent cytotoxic activity, the individual components (GA and
DZ analogs) were inactive. Thus, GA-DZ conjugates are new chemical entities and represent
interesting hits for anticancer drug discovery and development.
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1. Introduction
Triterpenoids, including glycyrrhetinic acid (GA) (1), oleanoic acid (OA) (2), and ursolic acid
(UA) (3), are widely distributed in the plant kingdom worldwide and show various
pharmacological activities. Structurally, OA and UA have a carboxylic acid on the C17 position
rather than the C20 position as in GA and also do not have a ketone at C11 as does GA. GA
(1) is the main constituent in the roots of the medicinal plant licorice (Glycyrrhiza glabra L),
which is broadly used as a flavoring and sweetening agent in food products. The wide-ranging
biological activities of GA include anti-inflammatory,1 anti-viral,2 anti-allergic,3,4 and
antitumor promoting effects.5 OA (2) and its regioisomer UA (3) also have interesting
biological activities.6 In addition, a well known phenolic natural product, dehydrozingerone
(DZ) (4), possesses anti-flammatory, antioxidant, and antitumor promoting activities.7
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Conjugation of two bioactive compounds is now accepted as an effective strategy for designing
ligands, inhibitors, and other drugs.8 Our group has implemented the conjugation approach in
drug discovery, which has led to promising results with varying compound classes.9 Therefore,
based on the diverse bioactivities of the above-mentioned terpenoids as well as DZ, we initiated
a structure activity relationship (SAR) study of terpenoid-DZ conjugation. Herein, we report
the syntheses of terpenoid-DZ analogs and their unique cytotoxic activities.
2. Results and discussion
Conjugation of DZ with the terpene acids GA, OA, and UA was achieved by a well known
esterification procedure using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDCI) as condensation reagent in the presence of 4-dimethylaminopyridine (DMAP). Among
the three initial conjugates, GA-DZ (5), OA-DZ (6), and UA-DZ (7), only compound 5
displayed significant cytotoxic activity as described later. This exciting finding prompted us
to synthesize novel GA-DZ analogs 29–38 as shown in Scheme 1. DZ (4) and its analogs (8–
17) were derived from the corresponding substituted benzaldehyde (18–28) with acetone or
acetophenone via an aldol reaction. The conjugated compounds 29–38 were obtained from the
resulting aldol products and GA using the same manner as described above.
Conjugates 5-7 were first evaluated against nasopharynx (KB) and multi-drug resistant KB
sub-line expressing P-glycoprotein (KB-VIN) cancer cell lines as shown in Table 1.
Interestingly, only GA-DZ (5) showed significant activity against these two cell lines with
ED50 values of 1.7 and 2.8 μM, respectively, whereas its individual components (GA and DZ)
were not active. OA-DZ (6) and UA-DZ (7) were also inactive. These results suggested that
not only was conjugation important, but that a ketone on C11 and/or the position of carboxylic
acid on C20 rather than C17 might be important factors for the activity. This exciting result
prompted us to explore additional novel GA-DZ analogs 29–38.
All GA-DZ analogs 29–38 as well as GA-DZ (5) itself were tested against nine human tumor
cell lines: KB, KB-VIN, lung (A549), ovarian (1A9), colon (HCT-8), breast (ZR-751), and
prostate (PC-3, DU-145 and LN-Cap).10-13 Doxorubicin was used as a positive antitumor
drug control, and GA and DZ were tested for comparison with the conjugates. The bioassay
results are shown in Table 2.
These results indicate that, while conjugation between GA and DZ is necessary for significant
cytotoxicity, the different substitution patterns on the DZ portion obviously affected the
selectivity as well as activity against the nine tested cancer cell lines. Generally, conjugate
31, with a 2-GA ester and 4-OMe, was remarkably less potent than 5, 29, and 30, which showed
significant cytotoxic effects against most of the cell lines with ED50 values less than 3.0 μM.
This result suggested that an ortho relation between the methoxy and GA ester groups might
be required for strong activity, possibly related to protein binding. Although both 29 and 31
bear the GA ester on the 2-position, 29 with 3-OMe showed broad spectrum cytotoxicity, while
31 with 4-OMe was selective against LN-Cap (EC50 = 1.9 μM) and HCT-8 (EC50 = 2.6 μM)
cell lines. Regarding cell line selectivity, conjugate 5 with 4-GA ester and 3-OMe showed its
highest potency (ED50 = 0.9 and 0.6 μM) against 1A9 and LN-Cap cells, respectively.
Comparatively, conjugate 29 with 2-GA ester and 3-OMe displayed stronger activities against
KB (EC50 = 0.8 μM), 1A9 (EC50 = 0.8 μM) and PC-3 (EC50 = 1.1 μM) than the remaining cell
lines, and conjugate 30 with 3-GA ester and 4-OMe showed its strongest activity against KB
cells with an ED50 value of 0.9 μM.
Replacing the methoxy (5, 29) with ethoxy (32, 33) caused decreased activity against all cell
lines, with loss of activity against KB-VIN, A549, ZR-751, and DU-145 cells. To a lesser
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extent, a similar trend was found with a meta-fluoro group (compare 29 and 34). Replacing
the methyl group at R2 with phenyl abolished the cytotoxic activity (see 35–38).
3. Conclusions
In summary, we found that conjugates between GA and DZ analogs showed significant
cytotoxic activity, although the individual components, GA and DZ, and similar conjugates
between DZ and similar terpenoids, OA and UA, did not. Novel GA-DZ analogs 5, 29, and
30, in which the methoxy and GA ester groups have an ortho relationship, showed significant
cytotoxic activity against most of the tested cell lines. More interestingly, different DZ
substitution patterns generated various cancer cell selectivities, with the highest potency
against LN-Cap (ED50 = 0.6 μM) and 1A9 (ED50 = 0.9 μM) for 5, KB (ED50 = 0.8 μM) and
1A9 (ED50 = 0.8 μM) for 29, KB (ED50 = 0.9 μM) for 30. Thus, GA-DZ conjugates represent
new hits for anticancer drug discovery and development.
4. Experimental
4.1. General
The proton nuclear magnetic resonance (1H-NMR) spectra were measured on a Varian Gemini
2000 (300 MHz) NMR spectrometer with TMS as the internal standard. All chemical shifts
are reported in ppm. Mass spectra were obtained on a Hitachi M-4100H mass spectrometer.
Analytical thin layer chromatography (TLC) was performed on Merck pre-coated aluminum
silica gel sheets (Kieselgel 60 F 254). Column chromatography was performed on a
CombiFlash Companion system using RediSep normal phase silica columns (ISCO, Inc.,
Lincoln, NE). All other chemicals were obtained from Aldrich, Inc. unless otherwise noted.
4.2. General Procedure for Aldol Reaction (4, 8–17)
The aldol intermediates were obtained by using the same procedure described by Elias and
Rao.14 For 4 and 8–13, acetone with 1N NaOH was used, and for 14–17, acetophenone in
MeOH with 5N KOH was used. Final compounds were purified with CombiFlash
chromatography (EtOAc-hexane gradient).
4.3. General Procedure for Esterification (5, 29–38)
A CH2Cl2 solution of the same mol ratio of the corresponding terpenoid and DZ analog (4, 8–
17) with a twofold mol ratio of EDCI and DMAP was stirred at room temperature under inert
atmosphere overnight. The crude mixture was extracted with CH2Cl2, and the organic phase
was washed with brine, dried over NaSO4, and concentrated in vacuo to obtain the product as
a solid. The crude solid was purified with CombiFlash chromatography (EtOAc-hexane
gradient).
4.3.1. DZ-GA conjugate (5)—1H NMR (300 MHz, CDCl3) δ 7.47 (d, 1H, J = 16.3 Hz, 1-
H), 7.17-7.12 (m, 2H, 2′-H and 6′-H), 7.01 (d, 1H, J = 8.1 Hz, 5′-H), 6.60 (d, 1H, J = 16.3 Hz,
2-H), 5.70 (br s, 1H, 12″-H), 3.87 (s, 3H, OCH3), 3.22 (br s, 1H, 3β-H), 2.78 (br d, 1H, J =
13.5 Hz, 1″β-H), 2.44-2.38 (m, 1H, 1″α-H), 2.39 (s, 3H, 4-H), 2.35 (s, 1H, 9″α-H), 1.40 (s, 3H,
CH3), 1.35 (s, 3H, CH3), 1.15 (s, 3H, CH3), 1.14 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.88 (s, 3H,
CH3), 0.81 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.22 (C11″, C=O in GA), 198.18
(C-3, C=O in DZ), 174.33 [C-30″, GA-C(O)O-DZ], 169.14 (C-13″, -C=C- in GA), 151.57
(C-3′) 142.76 [-CH=CHC(O)Me in DZ], 141.74 (C-4′), 133.29 (C-1′), 128.55 [-CH=CHC(O)
Me in DZ], 127.29 (=CH-), 123.21 (=CH-), 121.49 (=CH-), 111.25 (=CH-), 78.78 (C-3″, CH-
OH in GA), 61.83 (C-9″, CH), 55.74 (-OCH3 in DZ), 54.97 (C-5″, CH), 48.10 (C-18″, CH),
45.36, 44.44 and 43.21 (C-8′, 14″ and 20″), 41.27 (C-19”, CH2), 39.12 (C-1″ or 21″, CH2),
37.46 (C-21″ or 1″, CH2), 37.08 (C-10″ or C-4″), 32.79 (C-7″, CH2), 31.87 (C-4″, or C10″),
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31.21 (C-7″ or 21″, CH2), 28.54 (C-28″, CH3), 28.30 (C-24″, CH3), 28.11 (C-27″, CH3), 27.47
[C-1, -C(O)CH3], 27.31 (C-15″ or C-16″, CH2), 26.47 (C-16″ and C-15″, CH2×2), 23.40
(C-29″, CH3), 18.73 (CH3), 17.47 (C-6″, CH2), 16.35 (C-25″, CH3), 15.56 (C-23″, CH3); HR-
SIMS m/z 645.4159 [M+H]+ (calcd for C41H57O6, 645.4152).
4.3.2. DZ-OA conjugate (6)—1H NMR (300 MHz, CDCl3): δ 7.46 (d, 1H, J = 16.3 Hz, 1-
H), 7.16-7.10 (m, 2H, 2′-H and 6′-H), 6.97 (d, 1H, J = 8.1 Hz, 5′-H), 6.60 (d, 1H, J = 16.3 Hz,
2-H), 5.32 (br s, 1H, 12″-H), 3.83 (s, 3H, OCH3), 3.22 (br s, 1H, 3″α-H), 2.89 (m, 1H, 18″-H),
2.38 (s, 3H, 4-CH3), 1.19 (s, 3H, CH3), 1.00 (s, 3H, CH3), 0.94 (s, 3H, CH3), 0.92 (s, 3H,
CH3), 0.90 (s, 3H, CH3), 0.85 (s, 3H, CH3), 0.79 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3)
δ 198.23 (C-3, C=O in DZ), 175.48 (OA -C(O)O-DZ), 172.88 (C-13″, -C=C- in OA), 151.85
(C-3′), 143.20 [-CH=CHC(O)Me in DZ], 142.90 (C-4′), 142.20 (=CH-), 132.97 (C-1′), 127.09
[-CH=CHC(O)Me in DZ], 123.45 (=CH-), 123.04 (=CH-), 122.73 (=CH-), 111.20 (C′-2),
79.00 (C-3″, CH-OH in OA), 55.81 (-OCH3 in DZ), 55.23 (C-5″, CH), 48.35 (C-17″), 47.62
(C-9″, CH), 46.55 (C-19″, CH2), 41.80 (C-14″), 41.32 (C-18″, CH), 39.43 (C-8″), 38.75 (C-1″,
CH2), 38.47 (C-4″). 37.00 (C-10″), 33.79 (CH2), 33.26 (CH3), 33.00 (CH2), 32.56 (CH2), 31.63
(CH2), 30.67 (C-20″), 28.11 (CH3), 27.59 (CH2), 27.45 [-C(O)CH3], 27.19 (CH2), 25.81
(CH3), 23.61 (CH3), 23.44 (CH2), 23.08 (C H2), 18.33 (CH2), 17.21 (CH3), 15.45 (CH3), 15.30
(CH3); MS m/z 631 [M+H]+; HR-SIMS m/z 669.4005 [M+K]+ (calcd for C41H58O5K,
669.3921).
4.3.3. DZ-UA conjugate (7)—1H NMR (300 MHz, CDCl3): δ 7.46 (d, 1H, J = 16.3 Hz, 1-
H), 7.06 (dd, 1H, J = 8.1, 1.8 Hz, 6′-H), 7.09 (br s, 1H, 2′-H), 6.96 (d, 1H, J = 8.1 Hz, 5′-H),
6.60 (d, 1H, J = 16.3 Hz, 2-H), 5.31 (t, 1H, J = 3.9 Hz, 12″-H), 3.82 (s, 3H, OCH3), 3.21 (br
s, 1H, 3″α-H), 2.35 (d, 1H, J = 11.1 Hz, 18-H), 2.38 (s, 3H, 4-CH3), 1.13 (s, 3H, CH3), 1.00
(s, 3H, CH3), 0.97 (d, 3H, J = 6.3 Hz, CH3), 0.94 (s, 3H, CH3), 0.89 (d, 3H, J = 4.5 Hz,
CH3), 0.85 (s, 3H, CH3), 0.79 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 198.22 (C-3, C=O
in DZ), 175.22 (C-30”, -C(O)O-DZ), 151.86 (C-3′or 4′), 142.89 [-CH=CHC(O)Me in DZ],
142.21 (C-4′ or 3′), 137.70 (=CH-), 132.97 (C-1′), 127.09 [-CH=CHC(O)Me in DZ], 126.02
(=CH-), 123.41 (=CH-), 121.52 (=CH-), 111.21 (C-2′), 79.03 (C-3″, CH-OH in UA), 55.80 (-
OCH3 in DZ), 55.25 (C-5″, CH), 52.95 (C-18″ or 9″, CH), 48.78 (C-18″ or 9″, CH), 47.60
(C-17″), 42.26 (C-14″), 39.70 (C-8″), 39.19 (C-19″ or 20″, CH), 38.83 (C-19″ or 20″, CH),
38.76 (C-1″, CH2), 38.68 (C-4″), 37.00 (C-10″), 36.54 (CH2) 33.26 (CH3), 30.79 (CH2′), 28.15
(CH3), 27.46 [-C(O)CH3], 27.25 (CH2), 24.37 (CH2), 23.40 (CH2), 21.18 (CH3), 18.35
(CH2), 17.53 (CH3), 16.99 (CH3), 15.63 (CH3), 15.52 (CH3); HR-SIMS m/z 669.3967; [M
+K]+ (calcd for C41H58O5K, 669.3921).MS m/z 631 [M+H]+.
4.3.4. DZ-GA conjugate (29)—1H NMR (300 MHz, CDCl3) δ 7.56 (d, 1H, J = 16.4 Hz, 1-
H), 7.26-7.19 (m, 2H, 4′-H and 6′-H), 7.02-6.99 (m, 1H, 5′-H) 6.68 (d, 1H, J = 16.4 Hz, 2-H),
5.69 (s, 1H, 12″-H), 3.84 (s, 3H, OCH3), 3.23 (dd, 1H, J = 10.2, 6.3 Hz, 3″α-H), 2.77 (ddd,
1H, J = 13.7, 3.6, 3.6 Hz, 1″β-H), 2.53 (br-d, 1H, J = 13.7 Hz, 1″α-H) 2.35 (s, 1H, 9″α-H),
2.33 (s, 3H, 4-H), 1.45 (s, 3H, CH3), 1.41 (s, 3H, CH3), 1.15 (s, 3H, CH3), 1.13 (s, 3H, CH3),
1.01 (s, 3H, CH3), 0.91 (s, 3H, CH3), 0.81 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.16
(C11″, C=O in GA), 197.74 (C-3, C=O in DZ), 174.11 (C-30″, -C(O)O-DZ), 169.11 (C-13″,
-C=C- in GA), 161.61 (C-3′or 2′), 138.96 (C-2′ or 3′), 136.23 [-CH=CHC(O)Me in DZ], 129.22
(=CH-), 128.63 (=CH-), 128.54 (C-1′), 126.60 (=CH-), 118.38 (=CH-), 113.79 (=CH-), 78.75
(C-3″, CH-OH in GA), 61.82 (C-9″, CH), 55.80 (-OCH3 in DZ), 54.95 (C-5″, CH), 47.77
(C-18″, CH), 45.37, 44.68 and 43.20 (C-8′, 14″ or 20″), 41.27 (C-19″, CH2), 39.12 (C-1″ or
22″, CH2), 37.08 (C-10″), 32.78 (C-7″ or 21″, CH2), 31.88 (C-4″), 31.30 (C-7″ or 21″, CH2),
28.62 (CH3), 28.54 (CH3), 28.09 (CH3), 27.50 [-C(O)CH3], 27.29 (CH2), 26.53 (CH2), 26.40
(C-16″ or -15″, CH2), 23.42 (C-29″, CH3), 18.71 (CH3), 17.49 (C-6”, CH2), 16.33 (C-25″,
CH3), 15.56 (C-23″, CH3); HR-SIMS m/z 645.4160 [M+H]+ (calcd for C41H57O6, 645.4152).
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4.3.5. DZ-GA conjugate (30)—1H NMR (300 MHz, CDCl3) δ 7.44 (d, 1H, J = 16.3 Hz, 1-
H), 7.40 (dd, 1H, J = 8.5, 2.2 Hz, 6′-H), 7.20 (d, 1H, J = 2.2 Hz, 2′-H), 6.98 (d, 1H, J = 8.5 Hz,
5′-H) 6.59 (d, 1H, J = 16.3 Hz, 2-H), 5.70 (s, 1H, 12″-H), 3.87 (s, 3H, OCH3), 3.22 (m, 1H, 3″
α-H), 2.78 (ddd, J = 13.5, 3.5, 3.5 Hz, 1″β-H), 2.42 (br-d, 1H, J = 13.5, 2.8 Hz, 1″α-H), 2.37
(s, 3H, 4-H), 2.35 (s, 1H, 9″α-H), 1.40 (s, 3H, CH3), 1.37 (s, 3H, CH3), 1.15 (s, 3H, CH3), 1.14
(s, 3H, CH3), 1.01 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.81 (s, 3H, CH3); 13C NMR (300 MHz,
CDCl3) δ 200.24 (C11″, C=O in GA), 198.21 (C-3, C=O in DZ), 174.42 (C-30″, -C(O)O-DZ),
169.19 (C-13″, -C=C- in GA), 155.12 (C-3′or 4′), 142.34 [-CH=CHC(O)Me in DZ], 140.08
(C-4′ or 3′), 128.52 (=CH-), 127.77 (C-1′), 127.48 (=CH-), 125.94 (=CH-), 121.99 (=CH-),
112.40 (=CH-), 78.76 (C-3″, CH-OH in GA), 61.83 (C-9″, CH), 55.86 (-OCH3 in DZ), 54.94
(C-5″, CH), 48.07 (C-18″, CH), 45.39, 44.42 and 43.20 (C-8’, 14″ or 20″), 41.25 (C-19″,
CH2), 39.13 (C-1″ or 22″, CH2), 37.45 (C-10”), 37.08 (C-1″ or 22″, CH2), 32.78 (C-7″ or 21″,
CH2), 31.88 (C-4″), 31.22 (C-7″ or 21″, CH2), 28.58 (CH3), 28.34 (CH3), 28.09 (CH3), 27.44
[-C(O)CH3], 27.30 (CH2), 26.53 (CH2), 26.44 (C-16″ or -15″, CH2), 23.40 (C-29″, CH3), 18.71
(CH3), 17.49 (C-6”, CH2), 16.36 (C-25”, CH3), 15.57 (C-23”, CH3); HR-SIMS m/z 645.4157
[M+H]+ (calcd for C41H57O6, 645.4152).
4.3.6. DZ-GA conjugate (31)—1H NMR (300 MHz, CDCl3) δ 7.63 (d, 1H, J = 8.8 Hz, 6’-
H), 7.53 (d, 1H, J = 16.2 Hz, 1-H), 6.84 (dd, 1H, J = 8.8, 2.5 Hz, 5′-H) 6.56 (d, 1H, J = 2.5 Hz,
3′-H), 6.61 (d, 1H, J = 16.2 Hz, 2-H), 5.67 (s, 1H, 12″-H), 3.85 (s, 3H, OCH3), 3.23 (ddd, 1H,
J = 9.9, 6.3, 6.3 Hz, 3″α-H), 2.78 (ddd, J = 13.7, 3.5, 3.5 Hz, 1″β-H), 2.30 (br-d, 1H, J = 13.7,
3.5 Hz, 1″α-H), 2.31 (s, 3H, 4-H), 2.35 (s, 1H, 9″α-H), 1.45 (s, 3H, CH3), 1.40 (s, 3H, CH3),
1.14 (s, 3H, CH3), 1.13 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.81 (s, 3H,
CH3); 13C NMR (300 MHz, CDCl3) δ 199.99 (C11″, C=O in GA), 197.63 (C-3, C=O in DZ),
174.63 (C-30″, -C(O)O-DZ), 168.40 (C-13″, -C=C- in GA), 162.22 (C-4′or 2′), 150.98 (C-4′
or 2′), 136.01 (=CH-), 128.80 (=CH-), 128.11 (=CH-), 126.48 (=CH-), 120.00 (C-1′), 112.48
(=CH-), 108.46 (=CH-), 78.76 (C-3″, CH-OH in GA), 61.84 (C-9″, CH), 55.65 (-OCH3 in DZ),
54.96 (C-5″, CH), 48.24 (C-18″, CH), 45.39, 44.63 and 43.22 (C-8′, 14″ or 20″), 41.04 (C-19″,
CH2), 39.12 (C-1″ or 22″, CH2), 37.91 (C-1″ or 22″, CH2), 37.11 (C-10″), 32.79 (C-7″ or 21″,
CH2), 31.98 (C-4″), 31.24 (C-7″ or 21″, CH2), 28.57 (CH3), 28.30 (CH3), 28.10 (CH3), 27.64
[-C(O)CH3], 27.31 (CH2), 26.46 (CH2), 26.39 (CH2), 23.46 (C-29″, CH3), 18.70 (CH3), 17.50
(C-6″, CH2), 16.34 (C-25″, CH3), 15.55 (C-23″, CH3); HR-SIMS m/z 645.4145 [M+H]+ (calcd
for C41H57O6, 645.4152).
4.3.7. DZ-GA conjugate (32)—1H NMR (300 MHz, CDCl3) δ 7.47 (d, 1H, J = 16.2 Hz, 1-
H), 7.13 (dd, 1H, J = 8.0, 1.9 Hz, 6′-H), 7.11 (d, 1H, J = 1.9 Hz, 2′-H), 6.98 (d, 1H, J = 8.0 Hz,
5′-H) 6.59 (d, 1H, J = 16.2 Hz, 2-H), 5.71 (s, 1H, 12-H), 4.10 (q, 2H, J = 6.9 Hz, OCH2CH3),
3.23 (m, 1H, 3″α-H), 2.78 (ddd, J = 13.5, 3.4, 3.4 Hz, 1″β-H), 2.35-2.40 (m, 1H, 1″α-H), 2.39
(s, 3H, 4-H), 2.35 (s, 1H, 9″α-H), 1.40 (t, 3H, J = 6.9 Hz, OCH2CH3), 1.40 (s, 3H, CH3), 1.37
(s, 3H, CH3), 1.14 (s, 3H, CH3), 1.13 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.87 (s, 3H, CH3), 0.81
(s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.14 (C11″, C=O in GA), 198.25 (C-3, C=O
in DZ), 174.24 (C-30″, -C(O)O-DZ), 169.02 (C-13″, -C=C- in GA), 151.00 (C-4′or 3′), 142.88
[-CH=CHC(O)Me in DZ], 141.71 (C-4′ or 3′), 133.22 (C-1′), 128.63 (=CH-), 127.19 (=CH-),
123.67 (=CH-), 121.24 (=CH-), 111.96 (=CH-), 108.46 (=CH-), 78.75 (C-3″, CH-OH in GA),
64.23 (-OCH2CH3 in DZ), 61.82 (C-9″, CH), 54.94 (C-5″, CH), 48.11 (C-18″, CH), 45.39,
44.40 and 43.18 (C-8′, 14″ or 20″), 41.11 (C-19″, CH2), 39.12 (C-1″ or 22″, CH2), 37.62 (C-1″
or 22″, CH2), 37.09 (C-10″), 32.75 (C-7″ or 21″, CH2), 31.92 (C-4″), 31.14 (C-7″ or 21″,
CH2), 28.49 (CH3), 28.38 (CH3), 28.08 (CH3), 27.45 [-C(O)CH3], 27.29 (CH2), 26.50 (CH2),
26.43 (CH2), 23.45 (CH3), 18.68 (CH3), 17.47 (C-6″, CH2), 16.33 (C-25″, CH3), 15.55 (C-23″,
CH3), 14.85 (OCH2CH3 in DZ); HR-SIMS m/z 659.4315 [M+H]+ (calcd for C42H59O6,
659.4309).
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4.3.8. DZ-GA conjugate (33)—1H NMR (300 MHz, CDCl3) δ 7.59 (d, 1H, J = 16.5 Hz, 1-
H), 7.23-7.17 (m, 2H, 5′-H and 6′-H), 6.99 (dd, 1H, J = 6.8, 2.9 Hz, 4′-H), 6.68 (d, 1H, J = 16.5
Hz, 2-H), 5.70 (s, 1H, 12″-H), 4.10 (q, 2H, J = 6.9 Hz, OCH2CH3), 3.23 (m, 1H, 3″α-H), 2.78
(ddd, J = 9.9, 3.6, 3.6 Hz, 1″β-H), 2.49 (m, 1H, 1″α-H), 2.33 (s, 3H, 4-H), 2.35 (s, 1H, 9″α-H),
1.39 (t, 3H, J = 6.9 Hz, OCH2CH3), 1.46 (s, 3H, CH3), 1.41 (s, 3H, CH3), 1.14 (s, 3H, CH3),
1.23 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.91 (s, 3H, CH3), 0.81 (s, 3H, CH3); 13C NMR (300
MHz, CDCl3) δ 200.07 (C11″, C=O in GA), 197.66 (C-3, C=O in DZ), 174.03 (C-30″, -C(O)
O-DZ), 168.97 (C-13″, -C=C- in GA), 150.98 (C-2′or 3′), 138.96 (C-2′ or 3′), 136.35 (=CH-),
129.11 (=CH-), 128.78 (=CH-), 128.69 (=CH-), 126.56 (=CH-), 118.07 (=CH-), 114.38
(=CH-), 78.76 (C-3″, CH-OH in GA), 64.28 (-OCH2CH3 in DZ), 61.83 (C-9″, CH), 54.95
(C-5″, CH), 47.69 (C-18″, CH), 45.39, 44.64 and 43.17 (C-8′, 14″ or 20″), 41.07 (C-19″,
CH2), 39.12 (C-1″ or 22″, CH2), 37.80 (C-1″ or 22″, CH2), 37.09 (C-10″), 32.75 (C-7″ or 21″,
CH2), 31.96 (C-4″), 31.27 (C-7″ or 21″, CH2), 28.92 (CH3), 28.43 (CH3), 28.09 (CH3), 27.72
[-C(O)CH3], 27.30 (CH2), 26.50 (CH2), 26.36 (CH2), 23.54 (CH3), 18.70 (CH3), 17.49 (C-6″,
CH2), 16.34 (C-25″, CH3), 15.56 (C-23″, CH3), 14.92 (OCH2CH3 in DZ); HR-SIMS m/z
659.4311 [M+H]+ (calcd for C42H59O6, 659.4309).
4.3.9. DZ-GA conjugate (34)—1H NMR (300 MHz, CDCl3) δ 7.53 (d, 1H, J = 16.5 Hz, 1-
H), 7.45-7.17 (m, 3H, 4′, 5′, and 6’-H), 6.72 (d, 1H, J = 16.5 Hz, 2-H), 5.68 (s, 1H, 12″-H),
3.23 (m, 1H, 3″α-H), 2.78 (ddd, J = 9.6, 6.0, 6.0 Hz, 1″β-H), 2.38 (m, 1H, 1″α-H), 2.35 (s, 3H,
4-H), 2.35 (s, 1H, 9″α-H), 1.45 (s, 3H, CH3), 1.40 (s, 3H, CH3), 1.14 (s, 3H, CH3), 1.13 (s, 3H,
CH3), 1.01 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.81 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3)
δ 200.11 (C11″, C=O in GA), 197.36 (C-3, C=O in DZ), 173.75 (C-30″, -C(O)O-DZ), 168.61
(C-13”, -C=C- in GA), 156.26 (C-3′or 2′), 137.54 (C-3′ or 2′), 134.99 (=CH-), 129.97 (C-1′),
129.76 (=CH-), 128.76 (=CH-), 126.93 (=CH-), 122.29 (=CH-), 118.18 (=CH-), 78.77 (C-3″,
CH-OH in GA), 61.83 (C-9″, CH), 54.96 (C-5″, CH), 47.98 (C-18″, CH), 45.38, 44.82 and
43.18 (C-8′, 14″ or 20″), 41.16 (C-19″, CH2), 39.13 (C-1″ or 22″, CH2), 37.57 (C-1″ or 22″,
CH2), 37.10 (C-10″), 32.78 (C-7″ or 21″, CH2), 31.89 (C-4″), 31.29 (C-7″ or 21″, CH2), 28.42
(CH3), 28.38 (CH3), 28.10 (CH3), 27.79 [-C(O)CH3], 27.31 (CH2), 26.49 (CH2), 26.41
(CH2), 23.43 (CH3), 18.70 (CH3), 17.49 (C-6″, CH2), 16.34 (C-25″, CH3), 15.61 (C-23″,
CH3); HR-SIMS m/z 633.3949 [M+H]+ (calcd for C40H54O5F5, 633.3953).
4.3.10. DZ-GA conjugate (35)—1H NMR (300 MHz, CDCl3) δ 8.03-7.49 (m, 5H, 2‴-
6‴-H) 7.77 (d, 1H, J = 15.8 Hz, 1-H), 7.46 (d, 1H, J = 15.8 Hz, 2-H), 7.26 (dd, 1H, J = 8.3
Hz, 6′-H), 7.21 (d, 1H, J = 1.9 Hz, 2′-H), 7.04 (d, 1H, J = 8.3 Hz, 5′-H), 5.71 (s, 1H, 12″-H),
3.90 (s, 3H, OCH3), 3.23 (dd, 1H, J = 10.0, 5.9 Hz, 3″α-H), 2.78 (ddd, 1H, J = 13.5, 3.2, 3.2
Hz, 1″β-H), 2.41 (br-d, 1H, J = 13.5 Hz, 1″α-H), 2.35 (s, 1H, 9″α-H), 1.40 (s, 3H, CH3), 1.37
(s, 3H, CH3), 1.16 (s, 3H, CH3), 1.14 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.81
(s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.48 (C11″ C=O in GA), 190.80 (C-3, C=O
in DZ), 174.58 (C-30″, -C(O)O-DZ), 169.40 (C-13″, -C=C- in GA), 151.78 (C-4′or 3′), 144.51
[-CH=CHC(O)Ph in DZ], 141.95 (C-4′ or 3′), 138.43 (C-4), 133.99 (C-1′), 133.03 (=CH-),
128.87 (C×2 in Ph), 128.76 (C×2 in Ph), 123.44 (=CH-), 122.57 (=CH-), 121.62 (=CH-), 112.03
(=CH-), 79.01 (C-3″, CH-OH in GA), 62.07 (C-9”, CH), 56.03 (-OCH3 in DZ), 55.19 (C-5″,
CH), 48.33 (C-18″, CH), 45.63, 44.68 and 43.45 (C-8′, 14″ or 20″), 41.52 (C-19”, CH2), 39.36
(C-1″ or 22″, CH2), 37.69 (C-1″ or 22″, CH2), 37.32 (C-10″), 33.02 (C-7″ or 21″, CH2), 32.12
(C-4″), 31.46 (C-7″ or 21″, CH2), 28.80 (CH3), 28.54 (CH3), 28.32 (CH3), 27.55 (CH2), 26.69
(CH2), 23.64 (CH2), 18.95 (CH3), 17.73 (C-6″, CH2), 16.60 (C-25″, CH3), 15.80 (C-23″,
CH3); HR-SIMS m/z 707.4306 [M+H]+ (calcd for C46H59O6, 707.4309).
4.3.11. DZ-GA conjugate (36)—1H NMR (300 MHz, CDCl3) δ 8.00-7.46 (m, 5H,
2‴-6‴-H) 7.84 (d, 1H, J = 15.9 Hz, 1-H), 7.48 (d, 1H, J = 15.9 Hz, 2-H), 7.38 (dd, 1H, J =
8.1, 1.5 Hz, 6′-H), 7.25 (dd, 1H, J = 8.1, 8.1 Hz, 5′-H), 7.03 (dd, 1H, J = 8.1, 1.5 Hz, 4′-H),
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5.69 (s, 1H, 12″-H), 3.85 (s, 3H, OCH3), 3.23 (m, 1H, 3″α-H), 2.77 (ddd, 1H, J = 13.5, 3.4,
3.4 Hz, 1″β-H), 2.77 (ddd, 1H, J = 13.5, 3.4, 3.4 Hz, 1″α-H), 2.34 (s, 1H, 9″α-H), 1.40 (s, 3H,
CH3), 1.40 (s, 3H, CH3), 1.14 (s, 3H, CH3), 1.13 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.88 (s, 3H,
CH3), 0.80 (s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.17 (C11″, C=O in GA), 190.24
(C-3, C=O in DZ), 174.24 (C-30″, -C(O)O-DZ), 151.74 (C-13″, -C=C- in GA), 139.27 (C-2′
or 3′), 138.05 (C-2′ or 3′), 137.73 (=CH-), 132.74 (=CH-), 129.17 (C-4), 128.60 (C×2 in Ph),
128.50 (C×2 in Ph), 126.63 (=CH-), 124.47 (=CH-), 118.30 (=CH-), 113.81 (=CH-), 78.76
(C-3″, CH-OH in GA), 61.80 (C-9″, CH), 55.84 (-OCH3 in DZ), 54.95 (C-5″, CH), 47.79
(C-18″, CH), 45.37, 44.68 and 43.20 (C-8′, 14″ or 20″), 41.30 (C-19″, CH2), 39.12 (C-1″ or
22″, CH2), 37.47 (C-1″ or 22″, CH2), 37.08 (C-10″), 32.79 (C-7″ or 21″, CH2), 31.85 (C-4″),
31.31 (C-7″ or 21″, CH2), 28.55 (CH3), 28.51 (CH3), 28.09 (CH3), 27.30 (CH2), 26.55
(CH2), 26.42 (CH2), 23.39 (CH3), 18.71 (CH3), 17.50 (C-6″, CH2), 16.34 (C-25″, CH3), 15.56
(C-23″, CH3); HR-SIMS m/z 707.4315 [M+H]+ (calcd for C46H59O6, 707.4309).
4.3.12. DZ-GA conjugate (37)—1H NMR (300 MHz, CDCl3) δ 8.02-7.45 (m, 5H,
2‴-6‴-H) 7.74 (d, 1H, J = 15.7 Hz, 1-H), 7.39 (d, 1H, J = 15.7 Hz, 2-H), 7.49 (dd, 1H, J =
8.3 Hz, 6′-H), 7.31 (d, 1H, J = 1.9 Hz, 2′-H), 7.00 (d, 1H, J = 8.5 Hz, 5′-H), 5.72 (s, 1H, 12″-
H), 3.89 (s, 3H, OCH3), 3.23 (m, 1H, 3″α-H), 2.78 (dm, 1H, J = 13.7 Hz, 1″β-H), 2.44 (dm,
1H, J = 13.7 Hz, 1″α-H), 2.35 (s, 1H, 9″α-H), 1.40 (s, 3H, CH3), 1.39 (s, 3H, CH3), 1.16 (s,
3H, CH3), 1.14 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.81 (s, 3H, CH3); 13C
NMR (300 MHz, CDCl3) δ 200.21 (C11″, C=O in GA), 190.53 (C-3, C=O in DZ), 174.45
(C-30″, -C(O)O-DZ), 169.19 (C-13″, -C=C- in GA), 153.17 (C-4′or 3′), 143.85 [-CH=CHC
(O)-Ph in DZ], 140.10 (C-4′ or 3′), 138.33 (C-4), 132.61 (=CH-), 128.57 (C×2 in Ph), 128.47
(C×2 in Ph), 128.28 (=CH-), 128.15 (=CH-), 128.03 (C-1′), 121.93 (=CH-), 120.89 (=CH-),
112.38 (=CH-), 78.76 (C-3″, CH-OH in GA), 61.82 (C-9″, CH), 55.86 (-OCH3 in DZ), 54.94
(C-5″, CH), 48.00 (C-18″, CH), 45.39, 44.42 and 43.20 (C-8′, 14″ or 20″), 41.28 (C-19″,
CH2), 39.12 (C-1″ or 22″, CH2), 37.47 (C-1″ or 22″, CH2), 37.08 (C-10″), 32.77 (C-7″ or 21″,
CH2), 31.89 (C-4″), 31.25 (C-7″ or 21″, CH2), 28.58 (CH3), 28.39 (CH3), 28.09 (CH3), 27.30
(CH2), 26.53 (CH2), 26.45 (CH2), 23.41 (CH3), 18.71 (CH3), 17.49 (C-6″, CH2), 16.36 (C-25″,
CH3), 15.57 (C-23″, CH3); HR-SIMS m/z 707.4305 [M+H]+ (calcd for C46H59O6, 707.4309).
4.3.13. DZ-GA conjugate (38)—1H NMR (300 MHz, CDCl3) δ 7.99-7.45 (m, 5H, Ar-H)
7.82 (d, 1H, J = 15.7 Hz, 1-H), 7.40 (d, 1H, J = 15.7 Hz, 2-H), 7.77 (dd, 1H, J = 8.5 Hz, 6′-H),
6.87 (dd, 1H, J = 8.8, 2.5 Hz, 5′-H), 6.59 (d, 1H, J = 2.5 Hz, 3′-H), 5.66 (s, 1H, 12″-H), 3.87
(s, 3H, OCH3), 3.22 (dd, 1H, J = 10.0, 6.2 Hz, 3″α-H), 2.76 (ddd, 1H, J = 13.5, 3.3, 3.3 Hz, 1″
β-H), 2.29 (br-dd, 1H, J = 13.5, 4.6 Hz, 1″α-H), 2.34 (s, 1H, 9″α-H), 1.41 (s, 3H, CH3), 1.39
(s, 3H, CH3), 1.12 (s, 3H, CH3), 1.12 (s, 3H, CH3), 1.00 (s, 3H, CH3), 0.86 (s, 3H, CH3), 0.80
(s, 3H, CH3); 13C NMR (300 MHz, CDCl3) δ 200.02 (C11″, C=O in GA), 190.27 (C-3, C=O
in DZ), 174.74 (C-30″, -C(O)O-DZ), 168.57 (C-13″, -C=C- in GA), 162.26 (C-4′or 2′), 151.29
(C-4′ or 2′), 138.33 (C-4), 137.61 (=CH-), 132.55 (=CH-), 128.73 (=CH-), 128.55 (C×2 in Ph),
128.42 (C×2 in Ph), 128.00 (=CH-), 121.61 (=CH-), 120.56 (C-1′), 112.53 (=CH-), 108.40
(=CH-), 78.77 (C-3″, CH-OH in GA), 61.80 (C-9″, CH), 55.68 (-OCH3 in DZ), 54.93 (C-5″,
CH), 48.22 (C-18″, CH), 45.38, 44.632 and 43.20 (C-8′, 14″ or 20″), 41.04 (C-19″, CH2), 39.12
(C-1″ or 22″, CH2), 37.80 (C-1″ or 22″, CH2), 37.07 (C-10″), 32.78 (C-7″ or 21″, CH2), 31.95
(C-4″), 31.24 (C-7″ or 21″, CH2), 28.53 (CH3), 28.29 (CH3), 28.09 (CH3), 27.30 (CH2), 26.46
(CH2), 26.38 (CH2), 23.44 (CH3), 18.69 (CH3), 17.49 (C-6″, CH2), 16.35 (C-25″, CH3), 15.56
(C-23″, CH3); HR-SIMS m/z 707.4320 [M+H]+ (calcd for C46H59O6, 707.4309).
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Structures of GA, OA, UA, DZ, and their conjugates.
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Syntheses of GA-DZ conjugates 29–38.
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Table 1
Cytotoxicity screening of DZ-terpenoid conjugates
Compound ED50 (μM)
a / Cell lineb
KB KB-VIN
5 (GA-DZ) 1.7 2.8
6 (OA-DZ) NAc NA






 Cytotoxicity as ED50 values for each cell line, the concentration of compound that cause 50% reduction in absorbance at 562 nm relative to untreated
cells using the sulforhodamine B assay. The average value is from two independent determinations and variation (SEM) was no greater than 10%.
b
 Human epidermoid carcinoma of the nasopharynx (KB), multi-drug resistant KB sub-line expressing P-glycoprotein (KB-VIN)
c
 Not active
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